A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.

Abstract

Platelet-activating factor (PAF) is a potent endogenous proinflammatory mediator implicated in the pathogenesis of septic shock. A double-blind randomized placebo-controlled trial of an intravenous PAF receptor antagonist (lexipafant) was conducted with 131 adult Thai patients with suspected severe sepsis (66 of whom had positive blood cultures). Detailed serial clinical, biochemical, and cytokine measurements were performed. Lexipafant treatment was well tolerated. The 28-day mortality in the lexipafant group (61.4%) was similar to that in the placebo group (62.6%). There was also no evidence that lexipafant affected clinical or biochemical measures of disease severity or the profile of sequentially measured plasma cytokine levels. PAF may not have an important role in the pathogenesis of severe sepsis.

• Authors: Y Suputtamongkol, S Intaranongpai, M D Smith, B Angus, W Chaowagul, C Permpikul, J A Simpson, A Leelarasamee, L Curtis, N J White
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 44 Issue 3 Pg. 693-6 (Mar 2000) ISSN: 0066-4804 [Print] United States
• PMID: 10681340 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Cytokines
• Imidazoles
• Lactates
• Platelet Membrane Glycoproteins
• Receptors, Cell Surface
• Receptors, G-Protein-Coupled
• platelet activating factor receptor
• Leucine
• lexipafant

Topics

• Bacterial Infections (drug therapy, immunology, microbiology, mortality)
• Cytokines (blood)
• Double-Blind Method
• Humans
• Imidazoles (adverse effects, therapeutic use)
• Lactates (blood)
• Leucine (adverse effects, analogs & derivatives, therapeutic use)
• Platelet Membrane Glycoproteins (antagonists & inhibitors)
• Receptors, Cell Surface
• Receptors, G-Protein-Coupled
• Sepsis (drug therapy, immunology, mortality)